Clinical Trial Update: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 randomized trial assessed continuous subcutaneous infusion of NN1218 formulations and NovoLog in people with Type 1 diabetes; the study is reported as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• NN1218
• NovoLog (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED